The pharmacokinetics and pharmacodynamics pathway of capecitabine, an agent used in the treatment of several cancers. Capecitabine is a prodrug that is enzymatically converted to 5-fluorouracil which inhibits the activity of thymidylate synthase necessary for the de novo DNA synthesis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.